Methods for diagnosis of maculopathies
AssigneeHadasit Medical Research Services and Development Ltd.
InventorsItay Chowers, Avraham Weiss, Michal Lederman
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for diagnosing a maculopathy. Specifically, the methods are based on determination of a level of at least one biological marker of a maculopathy in a bodily fluid sample of an individual (e.g. blood sample) and comparing the level of the assayed biological marker with the level of prior determined cut off standards. The level of the biological marker provides information regarding the state of the individual, such as whether the individual has the assayed maculopathy, is predisposed to develop said maculopathy, is responsive to treatment, and others.
Claims27
1-20. (canceled)
A method of determining a maculopathy, the method comprising:
- (a) determining a level of at least one biological marker of said maculopathy in a bodily fluid sample of the individual;
- and
- (b) comparing said level of said at least one biological marker with the level of prior determined standards, at least one standard that correlates level of said biological marker with a healthy state and one or more standards that correlate level of said biological marker with the existence of maculopathy, wherein
- a level of said biological marker having a deviation from said a prior determined standard for a healthy state is indicative that said individual has said maculopathy or that said individual is predisposed to develop said maculopathy;
- wherein said biological marker is selected from:
- (i) a nucleic acid molecule comprising a nucleic acid sequence as depicted in any one of sequences ID Nos. 1 to 22, a functional fragment, derivative or splice variant of same;
- or
- (ii) an expression product of (i) or a molecule comprising a functional fragment of said expression product.
A method for determining severity of a maculopathy in an individual comprising:
- (a) determining a level of at least one biological marker of said maculopathy in a bodily fluid sample of the individual;
- and
- (b) comparing said level of said at least one biological marker with the level of prior determined standards that correlate level of said biological marker with severity of maculopathy;
- wherein said biological marker is selected from:
- (i) a nucleic acid molecule comprising a nucleic acid sequence as depicted in any one of SEQ ID Nos. 1 to 22, a functional fragment, derivative or splice variant of said nucleic acid sequence;
- or
- (ii) an expression product of (i) or a molecule comprising a functional fragment of said expression product.
A method for determining the effectiveness of a maculopathy therapeutic treatment of an individual, the treatment comprises administering a therapeutic agent to the individual, the method comprises determining the level of at least one biological marker of said maculopathy in a bodily fluid sample obtained from said individual, in two or more successive time points, one or more of which is during therapeutic treatment, wherein a difference in the level being indicative of effectiveness of the therapeutic treatment;
- wherein said biological marker is selected from:
- (a) a nucleic acid molecule comprising a nucleic acid sequence as depicted in any one of SEQ ID Nos. 1 to 22, a functional fragment, derivative or splice variant of said nucleic acid sequence;
- or
- (b) an expression product of (i) or a molecule comprising a functional fragment of said expression product.
A nucleic acid probe for use as an agent for determining in an individual a state of maculopathy or a predisposition to develop said maculopathy, the probe being at least 80% complementary with a nucleic acid molecule comprising a sequence disclosed in SEQ ID NOs. 1 to 22, or with a fragment, derivative or splice variant of a sequence from SEQ ID NOs. 1 to 22.
An oligonucleotide primer pair for use as an agent for determining in an individual a state of maculopathy, a predisposition to develop said maculopathy, said primer pair being at least 80% complementary with a portion of a nucleic acid molecule comprising a sequence disclosed in SEQ ID NOs. 1 to 22, or with a fragment, derivative or splice variant of the sequence from SEQ ID NOs. 1 to 22.
An antibody capable of binding to a biological marker within a bodily fluid sample of an individual, if present in the sample, the biological marker selected from:
- (i) a nucleic acid molecule comprising a nucleic acid sequence as depicted in any one of SEQ ID Nos. 1 to 22, a functional fragment, derivative or splice variant of said nucleic acid sequence;
- or
- (ii) an expression product of (i) or a molecule comprising a functional fragment of said expression product.
Dependencies are inferred from the claim text.